Tag: turned-down
-
UK okays Alexion drug costing up to 1.5 million pounds but wants price cut
A new drug to treat a rare inherited bone disorder that was developed by Alexion Pharmaceuticals and could cost up to 1.5 million pounds a year per patient has been cleared for limited use by Britain’s health cost watchdog. The National Institute for Health and Care Excellence (NICE), which had turned down Strensiq as too…